Skip to main content

Day: December 11, 2023

Testing “Shifts Left” with Docker’s Acquisition of AtomicJar

Dev-first approach to testing comes to Docker, shifting it to the left for improved integration testing, faster application delivery, and enhanced developer productivity PALO ALTO, Calif., Dec. 11, 2023 (GLOBE NEWSWIRE) — Docker, Inc.®, today announced it has acquired New York-based AtomicJar, a privately-held company behind the popular open source project Testcontainers. This acquisition, the seventh by Docker since 2019, continues the company’s focus on improving the end-to-end developer experience by acquiring startups to accelerate delivery of its vision. The acquisition is a mix of equity and cash. Other terms of the deal were not disclosed. “With its support for Java, .NET, Node.js, and other programming languages together with its container-based testing automation, Testcontainers has become the de facto standard test framework...

Continue reading

Mandatory notification of trade and acceptance by primary insiders

Reference is made to the stock exchange announcement on 7 December 2023 whereby BW Sirocco Holdings AS (the “Offeror“) announced the completion and settlement of the Offer and the acquisition of the Offeror of 30,000,561 shares, representing approximately 95.21% of the total number of shares in BW Ideol AS. The Offeror, being a close associate of Marco Beenen, the chairperson of the board of directors of BW Ideol AS, attach the required notifications of trade to this announcement. Further, mandatory notifications from other primary insiders and their related parties are also attached to this announcement. For further information, please contact: BW Ideol ASNicolas de Kerangal (Chief Financial & Partnerships Officer)+33 (0) 7 76 87 70 08 / ir@bw-ideol.com (mailto:ir@bw-ideol.com) BW Sirocco Holdings ASAnders S. Platou (Chief...

Continue reading

UniFirst Corporation Plans to Announce First Quarter Results on January 3, 2024

WILMINGTON, Mass., Dec. 11, 2023 (GLOBE NEWSWIRE) — UniFirst Corporation (NYSE: UNF) will report its Fiscal 2024 first quarter results on January 3, 2024 before the market opens. The Company will also hold a conference call at 9:00 a.m. Eastern Time on January 3, 2024 to discuss its quarterly financial results, business highlights and outlook. In addition, the Company may answer one or more questions concerning business and financial developments and trends, the Company’s view on earnings forecasts and other business and financial matters affecting the Company, some of the responses to which may contain information that has not been previously disclosed. A simultaneous live webcast of the call and replay will be available over the Internet at http://investors.unifirst.com. Headquartered in Wilmington, Mass., UniFirst Corporation...

Continue reading

CUEN – Unleashes the Power of Shareholder Influence – Unveils Proxy Vote Link and Ignites a Call to Action

Cuentas, Inc.’s announced shareholders are now able to cast their proxy votes in advance of the Annual Meeting of Shareholders scheduled for December 20, 2023, at 10 am (EDT). Launches electronic voting site and printed material distribution. MIAMI BEACH, FL, Dec. 11, 2023 (GLOBE NEWSWIRE) — Cuentas, Inc. (Nasdaq: CUEN & CUENW) (“CUEN” or “the Company”), the foremost developer of fully integrated cybersecurity, telecommunications, and financial applications for the unbanked and underbanked Hispanic market, announced the has filed a Definitive Proxy Statement for shareholders to elect directors and ratify the company’s independent registered public accounting firm. The Proxy also facilitates the introduction of any other business to be brought before the annual meeting for consideration. Cuentas, Inc. is empowering...

Continue reading

Sirona Biochem Initiates GlycoProteMim™ Trademark for Anti-Aging Molecule TFC-1326

VANCOUVER, British Columbia, Dec. 11, 2023 (GLOBE NEWSWIRE) — Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF), is making a strategic move in the world of advanced skincare solutions. Today, the company announces the trademarking of its groundbreaking anti-aging and anti-wrinkle molecule, TFC-1326, as GlycoProteMim™. This pivotal decision marks a significant milestone in Sirona Biochem’s mission to bring forth a new era of skincare innovation. The trademarking of GlycoProteMim™, filed with the Instituto Nacional da Propriedade Industrial (INPI) and the United States Trademark and Patent Office, demonstrates the company’s unwavering commitment to revolutionizing the cosmetics industry with cutting-edge science and unparalleled anti-aging solutions. With over two decades of research and development,...

Continue reading

The sales of „Vilvi Group“ November 2023

“Vilvi Group”, which consists of Vilkyškių pieninė AB, “Modest” AB, Kelmės pieninė AB, “Kelmės pienas” UAB, “Pieno logistika” AB and “Baltic Dairy Board” SIA, consolidated sales for November 2023 amounted to 19.69 million EUR 3.0% increase comparing to November 2022. The sales of the Group for period January – November 2023 amounted to 193.01 million EUR 10.1% decrease comparing to the same period last year. Vilija Milaseviciute Economics and finance directorPhone: +370 441 55 102

Continue reading

Sunrise New Energy Secures 10,000 Tons Incremental Order from Existing Customer Narada Power for 2024, 3 Times the Order for 2023

ZIBO, China, Dec. 11, 2023 (GLOBE NEWSWIRE) — Sunrise New Energy Co., Ltd. (“Sunrise”, the “Company”, “we” or “our”) (NASDAQ: EPOW), today announced that Narada Power, a leading player in the energy storage industry, has placed an incremental order for 10,000 tons of anode materials for the upcoming year, further solidifying their cooperation. Having successfully undergone a rigorous selection process, Sunrise emerged as one of the core suppliers for Narada Power, outstanding from fierce competition in previous bidding rounds. Sunrise is on track to fulfill the delivery of 3,500 tons of products to Narada Power as of the end of 2023. The latest order from Narada Power, amounting to 10,000 tons for 2024, demonstrates its continued trust and reliance on Sunrise’s expertise and products. “This order marks a significant...

Continue reading

Elevai Labs Inc Announces Financial Results for the Quarter Ended September 30, 2023

Company Records Record Quarterly Revenues NEWPORT BEACH, Calif., Dec. 11, 2023 (GLOBE NEWSWIRE) — Elevai Labs Inc. (NASDAQ: ELAB), a medical aesthetic company specializing in physician-dispensed skincare, today reported financial results for its Q3 2023 fiscal quarter, ended September 30, 2023. “We are proud to announce a record setting quarter for Elevai marked by exceptional growth in both revenue and gross profit,” said Jordan Plews, Elevai’s Chief Executive Officer. “In Q3, our revenue grew over 75% over the previous quarter and this growth is a testament to the effectiveness of our sales strategy and our team’s hard work. “Looking ahead, we remain committed to investing in the growth and scale of Elevai while maintaining our focus on operational efficiencies. Additionally, with our recent transition to a public company and...

Continue reading

SYLA Technologies Announces Business Collaboration with Private Fund Managed by BlackRock’s Real Estate Business

TOKYO, Dec. 11, 2023 (GLOBE NEWSWIRE) — SYLA Technologies Co., Ltd. (NASDAQ: SYT) (“SYLA” or “the Company”), operator of the largest membership real estate crowdfunding platform in Japan, Rimawari-kun, announced that the Company has entered into an agreement on business collaboration with a private fund managed by BlackRock’s Real Estate business on December 8, 2023. This marks SYLA’s first business collaboration with a major United States-based asset management firm. The agreement was concluded with the aim of strengthening mutual collaboration that includes providing BlackRock’s Real Estate business with opportunities to invest in Japanese properties developed by SYLA, particularly the Company’s own condominium brand, SYFORME series developed by SYLA Co. Ltd. (“SYLA Co.”), a wholly owned subsidiary of SYLA. Moving...

Continue reading

With 8.8% CAGR, UK Healthcare Consulting Market Size to Surpass USD 1.87 Billion by 2030

As per the report by Fortune Business Insights, The UK healthcare consulting market size was valued at USD 0.96 billion in 2022 and is predicted to reach USD 1.04 billion in 2023. The market is anticipated to touch USD 1.87 billion by 2030, recording a CAGR of 8.8% during the forecast period of 2023-2030.UK Healthcare Consulting MarketForecast 2023-2030Pune, India, Dec. 11, 2023 (GLOBE NEWSWIRE) — The UK healthcare consulting market size was valued at USD 0.96 billion in 2022 and market is anticipated to touch USD 1.87 billion by 2030 recording a CAGR of 8.8% during forecast period. Healthcare consulting offers support and implementation services for medical ecosystems to improve their operational and financial success. The rising incidence of chronic ailments among people across the U.K. and growing patient visits to...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.